HK1050856A1 - Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras - Google Patents

Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras

Info

Publication number
HK1050856A1
HK1050856A1 HK03103151A HK03103151A HK1050856A1 HK 1050856 A1 HK1050856 A1 HK 1050856A1 HK 03103151 A HK03103151 A HK 03103151A HK 03103151 A HK03103151 A HK 03103151A HK 1050856 A1 HK1050856 A1 HK 1050856A1
Authority
HK
Hong Kong
Prior art keywords
ras
angiogenesis
modulation
methods
protein kinase
Prior art date
Application number
HK03103151A
Other languages
English (en)
Inventor
John Hood
Brian Eliceiri
David A Cheresh
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of HK1050856A1 publication Critical patent/HK1050856A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK03103151A 1999-08-13 2003-05-02 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras HK1050856A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14892499P 1999-08-13 1999-08-13
US21595100P 2000-07-05 2000-07-05
PCT/US2000/021842 WO2001012210A1 (fr) 1999-08-13 2000-08-11 Techniques et compositions convenant pour la modulation de l'angiogenese a base de proteinekinase raf et de kinase ras

Publications (1)

Publication Number Publication Date
HK1050856A1 true HK1050856A1 (en) 2003-07-11

Family

ID=26846311

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103151A HK1050856A1 (en) 1999-08-13 2003-05-02 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras

Country Status (17)

Country Link
US (1) US20060040853A1 (fr)
EP (1) EP1210099A4 (fr)
JP (1) JP2003507337A (fr)
KR (2) KR100759241B1 (fr)
CN (1) CN1208087C (fr)
AU (1) AU781877B2 (fr)
BR (1) BR0013228A (fr)
CA (1) CA2380966A1 (fr)
CZ (1) CZ2002449A3 (fr)
HK (1) HK1050856A1 (fr)
HU (1) HUP0300923A3 (fr)
MX (1) MXPA02001553A (fr)
NO (1) NO20020718L (fr)
PL (1) PL364928A1 (fr)
RU (1) RU2257911C2 (fr)
SK (1) SK2142002A3 (fr)
WO (1) WO2001012210A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026246A2 (fr) * 2000-09-29 2002-04-04 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions pharmaceutiques contenant des polynucleotides codant une proteine raf
CN104030990B (zh) * 2007-03-12 2017-01-04 Ym生物科学澳大利亚私人有限公司 苯基氨基嘧啶化合物及其用途
WO2009091810A1 (fr) * 2008-01-14 2009-07-23 Genentech, Inc. Procédés pour inhiber l'angiogenèse au moyen d'antagonistes egfl8
EP2329854A3 (fr) * 2009-12-04 2014-02-19 Biotronik VI Patent AG Revêtement d'implant doté d'acides nucléiques
CN102766601B (zh) * 2011-11-17 2015-12-16 中山大学肿瘤防治中心 含有可诱导型癌基因的细胞系及其建立方法、应用
PL3151666T3 (pl) 2014-06-03 2020-05-18 Arturo Solis Herrera Modele zwierzęce angiogenezy rogówki oraz chorób rozstrzeniowych rogówki, sposoby wytwarzania i sposoby ich zastosowania
RU2728870C2 (ru) * 2017-10-12 2020-07-31 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Полипептиды для лечения онкологических заболеваний
EP4135738A2 (fr) * 2020-04-15 2023-02-22 Cohbar Inc. Procédé de traitement d'infections à coronavirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
US5618670A (en) 1988-08-26 1997-04-08 The United States Of America As Represented By The Department Of Health & Human Services Detection method for c-raf-1 genes
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5597719A (en) * 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US6300081B1 (en) * 1996-11-15 2001-10-09 Cornell Research Foundation, Inc. Activated ras interaction assay
AU9692198A (en) * 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods

Also Published As

Publication number Publication date
JP2003507337A (ja) 2003-02-25
AU6763300A (en) 2001-03-13
KR100759241B1 (ko) 2007-09-18
US20060040853A1 (en) 2006-02-23
CA2380966A1 (fr) 2001-02-22
CN1208087C (zh) 2005-06-29
KR100805098B1 (ko) 2008-02-20
CN1378457A (zh) 2002-11-06
SK2142002A3 (en) 2002-07-02
NO20020718L (no) 2002-04-10
BR0013228A (pt) 2003-06-17
KR20070067210A (ko) 2007-06-27
EP1210099A4 (fr) 2006-01-18
RU2257911C2 (ru) 2005-08-10
KR20020032553A (ko) 2002-05-03
WO2001012210A9 (fr) 2002-09-12
CZ2002449A3 (cs) 2002-08-14
HUP0300923A3 (en) 2005-12-28
WO2001012210A1 (fr) 2001-02-22
PL364928A1 (en) 2004-12-27
MXPA02001553A (es) 2003-05-23
HUP0300923A2 (hu) 2003-07-28
EP1210099A1 (fr) 2002-06-05
NO20020718D0 (no) 2002-02-12
AU781877B2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
HK1244797A1 (zh) 環蛋白酪氨酸激酶抑制劑
HUS1700048I1 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
HUP0103520A2 (hu) Protein tirozin kinázokat gátló hatású szubsztituált 3-cianokinolinok és ezeket tartalmazó gyógyászati készítmények
HK1172504A1 (en) Composition and methods for modulation of vascular structure and or function
EP1203092A4 (fr) Modulation antisens de l'expression de la map kinase kinase 6
AU4065000A (en) Antisense modulation of p38 mitogen activated protein kinase expression
HUP0203323A3 (en) Tyrosine kinase inhibitors and pharmaceutical compositions containing them
AU2396897A (en) 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
NO20021382D0 (no) Fremgangsmåter og mikroorganismer for fremstilling av panto- forbindelser
IL158588A0 (en) Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) - methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors
IL137041A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HUP0203746A3 (en) Novel composition and method for stabilizing the same
GB9903216D0 (en) Preservative compounds,compositions and methods of making and using the same
IL156334A0 (en) Methods for the production of multimeric proteins, and related compositions
HK1050856A1 (en) Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras
HUP0102614A3 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
AU6137801A (en) Method and composition for the treatment of angiogenesis
IL161057A0 (en) Composition and method for minimizing or avoiding adverse effects of vesicants
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
AU2003297554A8 (en) Modulation of death-associated protein kinase 1 expression
AU2002348191A1 (en) Method and composition for the modulation of angiogenesis
IL146505A (en) Methods for the preparation of tetrahydroisoquinolinephenol derivatives and some new such derivatives
AU2002353074A8 (en) Antisense modulation of pctaire protein kinase 1 expression
AU2404500A (en) Compositions and methods for stabilizing thiol-containing biomolecules
IL130879A0 (en) Method for the isolation and concentration of proteins

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100811